Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SER
SER logo

SER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.840
1 Day change
-5.64%
52 Week Range
7.920
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SER is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to invest. The pre-market price is slightly down, there is no strong proprietary buy signal, insiders are selling aggressively, there has been no recent news catalyst, and the technical setup is only mixed-to-neutral. With no clear fundamental support available and no strong near-term momentum signal, this is not an attractive entry for an impatient buyer looking to commit capital now.

Technical Analysis

SER is showing a mild mixed technical picture. MACD is positive and expanding, which is constructive, but RSI_6 at 62.54 is only neutral-to-mildly bullish rather than strong. Moving averages are converging, suggesting the stock is not in a strong trending phase. Price is trading near the pivot at 1.771, with pre-market price 1.93 sitting below first resistance at 1.969 and below R2 at 2.092, so upside is capped near-term unless it breaks resistance. The short-term pattern data also points to weakness over the next week, with an expected -3.25% move, which argues against an immediate long entry.

Positive Catalysts

  • Positive catalysts are limited. MACD remains above zero and expanding, which indicates some underlying momentum. Price is near the first resistance area, so a breakout above 1.969 could improve the setup. The estimated next-month pattern projection is slightly positive at 0.45%, but this is weak and not enough to outweigh the other signals.

Neutral/Negative Catalysts

  • Insiders are selling, and the selling amount has increased 489.78% over the last month, which is a major negative. Hedge funds are neutral with no meaningful accumulation trend. There is no recent news in the past week, so no event-driven catalyst is present. The stock-specific trend model projects -3.25% over the next week. Pre-market price is also down 1.03%, showing weak immediate sentiment. No AI Stock Picker signal and no SwingMax signal were triggered.

Financial Performance

No usable latest-quarter financial snapshot was available because the provided financial data returned an error. As a result, there is no reliable recent-quarter season to assess revenue, earnings, or growth trends from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street revision trend to support a bullish case. Based on the available information, Wall Street sentiment appears neutral at best, with more downside than upside evident from insider selling, the lack of catalyst, and the absence of strong buy signals. Pros: limited technical momentum and possible breakout potential above resistance. Cons: no recent upgrades, no price target support, no news catalyst, and heavy insider selling.

Wall Street analysts forecast SER stock price to rise
1 Analyst Rating
Wall Street analysts forecast SER stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.950
sliders
Low
11
Averages
11
High
11
Current: 1.950
sliders
Low
11
Averages
11
High
11
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$15
AI Analysis
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$15
AI Analysis
2025-07-14
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.

People Also Watch